



EXPRESS MAIL NUMBER  
EV33377499US

<b>Declaration Under 1.132</b>  Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Attorney Docket Confirmation No.	STAN-130
	First Named Inventor	Briesewitz
	Application Number	09/716,841
	Filing Date	November 17, 2000
	Group Art Unit	1651
	Examiner Name	David Naff
	Title	Bifunctional Molecules Having Modulated Pharmacokinetic Properties and Therapies Based Thereon

Dear Sir:

We, Dr. Thomas Wandless, Dr. Roger Briesewitz and Dr. Gerald Crabtree, do hereby declare as follows:

We are co-inventors of the above captioned patent application.

We are also a co-inventor of U.S. Patent No. 6,372,712, along with Gregory Thomas Ray and Kurt Vogel.

We understand that U.S. Patent No. 6,372,712 is being cited by the Patent Office to anticipate the claims of the above captioned application pursuant to 35 U.S.C. § 102(e).

U.S. Patent No. 6,372,712 discloses bifunctional molecules and their use in applications for enhancing one or more of a given drug's affinity, specificity or selectivity for its target.

The claims of U.S. Patent No. 6,372,712 are all directed to the bifunctional compounds disclosed in the patent, and the inventorship of these claims has been determined to be as listed on the face of the U.S. Patent No. 6,372,712.

In contrast to the composition of matter claims of the U.S. Patent No. 6,372,712 patent, the claims of the above-captioned application are directed to a particular use of bifunctional molecules, i.e., methods of modulating pharmacokinetic properties of a drug. To the extent that this particular application is disclosed in the specification of U.S. Patent No. 6,372,712 (if at all), this particular application was not conceived by either of Gregory Ray or Kurt Vogel.

Accordingly, we hereby declare that we are the sole inventors of the subject matter disclosed in the cited patent and relied on in the above-summarized rejection.



Atty Dkt. No.: STAN130

USSN: 09/716,841

We hereby declare that all statements made herein of our own knowledge are true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Date: \_\_\_\_\_

By \_\_\_\_\_  
Thomas Wandless, Ph.D.

Date: \_\_\_\_\_

By \_\_\_\_\_  
Roger Briesewitz, Ph.D.

Date: \_\_\_\_\_

By  \_\_\_\_\_  
Gerald Crabtree, Ph.D.